For instance, vorinostat, which is marketed under the name Zolinza® by Merck, is a potent HDAC inhibitor for treating cutaneous T-cell lymphoma but has been shown to cause bone loss during clinical trials of multiple myeloma [32]. This evidence concerns the gene HDAC9 and plasma cell myeloma.